Dr. Mark Ball is the Associate Program Director of the Urologic Oncology Fellowship and Senior Staff Surgeon at the National Cancer Institute of the National Institutes of Health. He is board-certified by the American Boards of Urology. He received his undergraduate degree in biochemistry and molecular biology from Centre College, graduating magna cum laude and Phi Beta Kappa. He received his M.D. from the Johns Hopkins University School of Medicine. He completed his internship and residency at the James Buchanan Brady Urological Institute at Johns Hopkin. He completed a Society of Urologic Oncology-accredited urologic oncology fellowship at the NCI where he worked in the laboratory of W. Marston Linehan.

Dr. Ball has been the recipient of several academic honors including election to the Alpha Omega Alpha honor society, outstanding laparoscopic surgeon from the Society of Laparoendoscopic Surgery, outstanding research from the Society of Urologic Oncology, recipient of an LRP award from the NIH, and multiple teaching awards.

Dr. Ball's research focuses on how tumor genetics translate into clinical behavior. He has authored over 100 peer-reviewed manuscripts and book chapters and regularly presents his work at national and international meetings. He is currently investigating the role of somatic mutations in the development of kidney cancer metastasis. Recent work has also focused on the role of somatic mutations in the response to checkpoint blockade in renal cell carcinoma.

Dr. Ball maintains a busy clinical practice, specializing in the surgical treatment kidney and adrenal tumors. He has removed over 700 kidney tumors during partial nephrectomy. He has a special focus on partial nephrectomy for kidney tumors, partial adrenalectomy for adrenal tumors, reoperative surgery in patients with a history of prior surgeries, and patients with multiple tumors.